Advanced search
Publication Cover
Cancer Investigation Volume 30, 2012 - Issue 10
Submit an article Journal homepage
303
Views
33
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Caio M. Rocha LimaDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,Correspondence[email protected]
,
Soley BayraktarDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Aurea M. FloresDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Jessica MacIntyreDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Alberto MonteroDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Joaquina C. BarandaDepartment of Medical Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA,
,
John WallmarkAssociates in Oncology/Hematology, PC, Rockville, Maryland, USA,
,
Chia PorteraGenentech, Inc., South San Francisco, California, USA
,
Rajiv RajaGenentech, Inc., South San Francisco, California, USA
,
Howard SternGenentech, Inc., South San Francisco, California, USA
,
Stephanie Royer-JooGenentech, Inc., South San Francisco, California, USA
&
Lukas C. AmlerGenentech, Inc., South San Francisco, California, USA
 show all
Pages 727-731 | Published online: 12 Oct 2012

Citations (33)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Alex Françoso & Patricia Ucelli Simioni. (2017) Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Design, Development and Therapy 11, pages 177-184.
Read now
Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:1.
Read now

Articles from other publishers (31)

Saisha A Nalawade, Paul Shafer, Pradip Bajgain, Mary K McKenna, Arushana Ali, Lauren Kelly, Jarrett Joubert, Stephen Gottschalk, Norihiro Watanabe, Ann Leen, Robin Parihar, Juan Fernando Vera Valdes & Valentina Hoyos. (2021) Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. Journal for ImmunoTherapy of Cancer 9:11, pages e003237.
Crossref
Lisa C. Holthof, Arwen Stikvoort, Hilma J. van der Horst, Anne T. Gelderloos, Renée Poels, Fengzhi Li, Richard W. J. Groen, Sonja Zweegman, Niels W. C. J. van de Donk, Michael O’Dwyer & Tuna Mutis. (2021) Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. HemaSphere 5:5, pages e561.
Crossref
Olivia A. Diaz Arguello & Hidde J. Haisma. (2021) Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. Cancers 13:7, pages 1543.
Crossref
Ke-Tao Jin, Bo Chen, Yu-Yao Liu, H uan-Rong Lan & Jie-Ping Yan. (2021) Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell International 21:1.
Crossref
Nikita Sharma, R. Mankamna Kumari, Geeta Arya, Nidhi Gupta, Ramesh Chandra & Surendra Nimesh. 2021. Clinical Perspectives and Targeted Therapies in Apoptosis. Clinical Perspectives and Targeted Therapies in Apoptosis 329 391 .
Chanchal Kumar, Rajat Pratap Singh, Mrigendra Kumar Dwiwedi & Ajay Amit. 2021. Colon Cancer Diagnosis and Therapy. Colon Cancer Diagnosis and Therapy 271 308 .
Bindu Thapa, Remant KC & Hasan Uludağ. (2020) TRAIL therapy and prospective developments for cancer treatment. Journal of Controlled Release 326, pages 335-349.
Crossref
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ángel R. Payer, Segundo Gonzalez & Alejandro López-Soto. (2020) Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer. International Journal of Molecular Sciences 21:10, pages 3726.
Crossref
Sonia How Ming Wong, Wei Yang Kong, Chee-Mun Fang, Hwei-San Loh, Lay-Hong Chuah, Syahril Abdullah & Siew Ching Ngai. (2019) The TRAIL to cancer therapy: Hindrances and potential solutions. Critical Reviews in Oncology/Hematology 143, pages 81-94.
Crossref
Lim, Greer, Lipkowitz & Takebe. (2019) Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers 11:8, pages 1087.
Crossref
Mostafa Akbarzadeh Khiavi, Azam Safary & Mohammad Hossein Somi. (2019) Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates. BioImpacts 9:3, pages 123-127.
Crossref
Sarah Alexandrou, Sandra George, Christopher Ormandy, Elgene Lim, Samantha Oakes & C. Caldon. (2019) The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. International Journal of Molecular Sciences 20:3, pages 667.
Crossref
M. V. Zabelin, S. S. Gordeev, S. O. Kochkina, A. A. Kostin, A. A. Fedenko, L. O. Petrov & E. V. Gameeva. (2018) New therapeutic agents for metastatic colorectal cancer: literature review. Colorectal Oncology 8:4, pages 34-46.
Crossref
Reyhaneh Moradi Marjaneh, Seyed Mahdi Hassanian, Niloofar Ghobadi, Gordon A. Ferns, Afshin Karimi, Mir Hadi Jazayeri, Mohammadreza Nasiri, Amir Avan & Majid Khazaei. (2018) Targeting the death receptor signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. Journal of Cellular Physiology 233:10, pages 6538-6549.
Crossref
Se-Lim Kim, In Suk Min, Young Ran Park, Soo Teik Lee & Sang-Wook Kim. (2018) Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer. International Journal of Oncology.
Crossref
Xiaona Wang, Qiang Xue, Liangliang Wu, Baogui Wang & Han Liang. (2018) Retracted: Dasatinib promotes TRAIL ‐mediated apoptosis by upregulating CHOP ‐dependent death receptor 5 in gastric cancer . FEBS Open Bio 8:5, pages 732-742.
Crossref
Agathe Dubuisson & Olivier Micheau. (2017) Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy. Antibodies 6:4, pages 16.
Crossref
Silvia von Karstedt, Antonella Montinaro & Henning Walczak. (2017) Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nature Reviews Cancer 17:6, pages 352-366.
Crossref
Elham Ajorlou, Ahmad Yari Khosroushahi & Hamid Yeganeh. (2016) Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model. Pharmaceutical Research 33:6, pages 1426-1439.
Crossref
Gustavo P. Amarante-Mendes & Thomas S. Griffith. (2015) Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacology & Therapeutics 155, pages 117-131.
Crossref
Marika CiprottiNiall C. TebbuttFook-Thean LeeSze-Ting LeeHui K. GanDavid C. McKeeGraeme J. O'KeefeSylvia J. GongGeoffrey ChongWendie HopkinsBridget ChappellFiona E. ScottMartin W. BrechbielArchie N. TseMendel JansenManabu MatsumuraMasakatsu KotsumaRira WatanabeRalph VenhausRobert A. BeckmanJonathan GreenbergAndrew M. Scott. (2015) Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology 33:24, pages 2609-2616.
Crossref
Amy V. Paschall, Dafeng Yang, Chunwan Lu, Jeong-Hyeon Choi, Xia Li, Feiyan Liu, Mario Figueroa, Nicholas H. Oberlies, Cedric Pearce, Wendy B. Bollag, Asha Nayak-Kapoor & Kebin Liu. (2015) H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance. The Journal of Immunology 195:4, pages 1868-1882.
Crossref
Xiaoyun Dai, Jingwen Zhang, Frank Arfuso, Arunachalam Chinnathambi, ME Zayed, Sulaiman Ali Alharbi, Alan Prem Kumar, Kwang Seok Ahn & Gautam Sethi. (2015) Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Experimental Biology and Medicine 240:6, pages 760-773.
Crossref
Kyriakos P. Papadopoulos, Randi Isaacs, Sanela Bilic, Kerstin Kentsch, Heather A. Huet, Matthias Hofmann, Drew Rasco, Nicole Kundamal, Zhongwhen Tang, Jennifer Cooksey & Amit Mahipal. (2015) Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody? targeting the DR5 receptor. Cancer Chemotherapy and Pharmacology 75:5, pages 887-895.
Crossref
Yabing Chen, Kaiyu Yuan & Jay McDonald. 2015. Resistance of Cancer Cells to CTL-Mediated Immunotherapy. Resistance of Cancer Cells to CTL-Mediated Immunotherapy 235 265 .
Julianne D. Twomey, William Hallett & Baolin Zhang. 2015. Resistance of Cancer Cells to CTL-Mediated Immunotherapy. Resistance of Cancer Cells to CTL-Mediated Immunotherapy 209 233 .
J Lemke, S von Karstedt, J Zinngrebe & H Walczak. (2014) Getting TRAIL back on track for cancer therapy. Cell Death & Differentiation 21:9, pages 1350-1364.
Crossref
Pamela M. Holland. (2014) Death receptor agonist therapies for cancer, which is the right TRAIL?. Cytokine & Growth Factor Reviews 25:2, pages 185-193.
Crossref
Giuseppe Giaccone & Jean-Charles SoriaPamela Holland, David Reese & Jeffrey Wiezorek. 2013. Targeted Therapies in Oncology, Second Edition. Targeted Therapies in Oncology, Second Edition 253 282 .
Thomas G Weber, Thomas Pöschinger, Stefanie Galbán, Alnawaz Rehemtulla & Werner Scheuer. (2013) Noninvasive Monitoring of Pharmacodynamics and Kinetics of a Death Receptor 5 Antibody and Its Enhanced Apoptosis Induction in Sequential Application with Doxorubicin. Neoplasia 15:8, pages 863-874.
Crossref
O Micheau, S Shirley & F Dufour. (2013) Death receptors as targets in cancer. British Journal of Pharmacology 169:8, pages 1723-1744.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.